Medicilon 美迪西
8 significant filings since 31 May 2026: 1 on litigation, 2 on change of interest and 2 on major holder selling, and 3 other kinds. The latest, on 22 Sep 2026: 美迪西：关于股东权益变动触及1%刻度的提示性公告. On 20 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 425.62% to 588.43% from the same period a year earlier.
自 31 May 2026 起有 8 份重大公告：litigation 1 份、change of interest 2 份、major holder selling 2 份，另有 3 类。最新一份（22 Sep 2026）：美迪西：关于股东权益变动触及1%刻度的提示性公告。20 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 425.62% 至 588.43%。
Price History 价格走势
1,675 trading days 个交易日 · High 最高 ¥395.90 · Low 最低 ¥23.83The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 5 Aug 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。